Valuation: Axsome Therapeutics, Inc.

Market Cap 10.76B 9.22B 8.64B 7.89B 14.9B 1,026B 15.04B 102B 39.68B 518B 40.41B 39.53B 1,714B P/E 2026 *
-76.8x
P/E 2027 * 44.6x
Enterprise Value 10.61B 9.09B 8.52B 7.78B 14.68B 1,011B 14.83B 100B 39.11B 510B 39.83B 38.96B 1,690B EV / Sales 2026 *
11x
EV / Sales 2027 * 6.61x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week-4.73%
Current month-5.74%
1 month-14.74%
3 months-12.92%
6 months+25.12%
Current year+12.51%
1 week 200.19
Extreme 200.1862
217.85
1 month 200.19
Extreme 200.1862
245.5
Current year 152.28
Extreme 152.28
260.19
1 year 112.9
Extreme 112.9
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 20.63
Extreme 20.63
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
8/6/26 Fiscal year

Chief Executive Officer

13,980 0.0272%
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/5/26 Free

Director

1,721 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%-4.73%+76.67%+168.04% 10.76B
+0.61%+2.88%+45.63%+0.39% 83.24B
-0.69%+3.58%-19.85%-35.64% 59.49B
+14.36%+152.27%+526.55%+41.90% 63.41B
+0.76%+3.53%+0.08%+36.18% 52.94B
-1.61%+1.24%+10.39%+168.31% 49.86B
+1.21%+3.87%+61.90%-16.51% 32.62B
+1.36%+5.06%+53.04%+103.13% 26.29B
+9.69%+11.76%+14.67%+215.97% 22.23B
-0.62%+0.34%+61.33%+123.11% 17.22B
Average +0.82%+17.98%+83.04%+80.49% 41.81B
Weighted average by Cap. +0.22%+26.54%+100.82%+52.10%

Financials

2026 *2027 *
Net sales 966M 828M 776M 709M 1.34B 92.11B 1.35B 9.15B 3.56B 46.47B 3.63B 3.55B 154B 1.56B 1.34B 1.25B 1.15B 2.16B 149B 2.18B 14.79B 5.76B 75.13B 5.87B 5.74B 249B
Net income -140M -120M -113M -103M -194M -13.38B -196M -1.33B -517M -6.75B -527M -515M -22.35B 255M 219M 205M 187M 353M 24.34B 357M 2.42B 941M 12.28B 959M 938M 40.67B
Net Debt -156M -134M -126M -115M -217M -14.92B -219M -1.48B -577M -7.53B -588M -575M -24.92B -435M -373M -350M -319M -603M -41.5B -609M -4.12B -1.61B -20.94B -1.63B -1.6B -69.34B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
26-08-26 $205.73 +0.12% 30,259
26-08-25 $205.48 +0.04% 731,550
26-08-24 $205.40 -1.14% 293,225
26-08-21 $207.77 -0.12% 734,950
26-08-20 $208.03 -4.66% 620,926
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
205.48USD
Average target price
285.42USD
Spread / Average Target
+38.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock